Primary CNS Lymphoma

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2017 Jun 23

PMID 28640701

Citations 252

Authors

Christian Grommes

Lisa M DeAngelis

Affiliations

Soon will be listed here.

Abstract

Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic spread. The prognosis of patients with PCNSL has improved during the last decades with the introduction of high-dose methotrexate. However, despite recent progress, results after treatment are durable in half of patients, and therapy can be associated with late neurotoxicity. PCNSL is an uncommon tumor, and only four randomized trials and one phase III trial have been completed so far, all in the first-line setting. To our knowledge, no randomized trial has been conducted for recurrent/refractory disease, leaving many questions unanswered about optimal first-line and salvage treatments. This review will give an overview of the presentation, evaluation, and treatment of immunocompetent patients with PCNSL.

Citing Articles

Mucosa-associated lymphoid tissue lymphoma of the dura mimicking meningioma: A case report.

Falcon Molina J, Lozano Guzman I, Rodriguez Florido M, Maciel Ramos E, Castillejo Adalid L, Ascencio Montiel M Surg Neurol Int. 2025; 16:63.

PMID: 40041086 PMC: 11878742. DOI: 10.25259/SNI_902_2023.

New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma.

Yang C, Ren X, Cui Y, Jiang H, Li M, Yu K Front Immunol. 2025; 16:1438001.

PMID: 40040699 PMC: 11876112. DOI: 10.3389/fimmu.2025.1438001.

Impact of Systemic and Radiation Therapy on Survival of Primary Central Nervous System Lymphoma.

Janopaul-Naylor J, Patel J, Rupji M, Hoang K, McCall N, Qian D Cancers (Basel). 2025; 17(4).

PMID: 40002213 PMC: 11853249. DOI: 10.3390/cancers17040618.

A Radiologist's Guide to IDH-Wildtype Glioblastoma for Efficient Communication With Clinicians: Part I-Essential Information on Preoperative and Immediate Postoperative Imaging.

Vollmuth P, Karschnia P, Sahm F, Park Y, Ahn S, Jain R Korean J Radiol. 2025; 26(3):246-268.

PMID: 39999966 PMC: 11865903. DOI: 10.3348/kjr.2024.0982.

Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience.

Hwang S, Godby R, Negaard B, Mwangi R, Nedved A, Barreto J Blood Adv. 2025; 9(4):924-932.

PMID: 39964705 PMC: 11876833. DOI: 10.1182/bloodadvances.2024014073.

References

del Rio M, Ricard D, Houillier C, Navarro S, Gonzalez-Aguilar A, Idbaih A . Prophylactic intrathecal chemotherapy in primary CNS lymphoma. J Neurooncol. 2011; 106(1):143-6. DOI: 10.1007/s11060-011-0649-7. View

Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K . Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol. 1996; 14(2):556-64. DOI: 10.1200/JCO.1996.14.2.556. View

Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82. DOI: 10.1182/blood-2003-05-1545. View

Weller M, Martus P, Roth P, Thiel E, Korfel A . Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol. 2012; 14(12):1481-4. PMC: 3499010. DOI: 10.1093/neuonc/nos159. View

Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V . Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015; 2(6):e251-9. DOI: 10.1016/S2352-3026(15)00074-5. View

Brugnoletti F, Morris E, Laningham F, Patay Z, Pauley J, Pui C . Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings. Pediatr Blood Cancer. 2008; 52(2):293-5. PMC: 2605174. DOI: 10.1002/pbc.21764. View

Omuro A, Correa D, DeAngelis L, Moskowitz C, Matasar M, Kaley T . R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015; 125(9):1403-10. PMC: 4342354. DOI: 10.1182/blood-2014-10-604561. View

Rubenstein J, Hsi E, Johnson J, Jung S, Nakashima M, Grant B . Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013; 31(25):3061-8. PMC: 3753699. DOI: 10.1200/JCO.2012.46.9957. View

Camilleri-Broet S, Martin A, Moreau A, Angonin R, Henin D, Gontier M . Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol. 1998; 110(5):607-12. DOI: 10.1093/ajcp/110.5.607. View

10.

Raizer J, Rademaker A, Evens A, Rice L, Schwartz M, Chandler J . Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer. 2011; 118(15):3743-8. DOI: 10.1002/cncr.26709. View

11.

Hottinger A, DeAngelis L, Yahalom J, Abrey L . Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology. 2007; 69(11):1178-82. DOI: 10.1212/01.wnl.0000276986.19602.c1. View

12.

Glass J, Gruber M, Cher L, Hochberg F . Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg. 1994; 81(2):188-95. DOI: 10.3171/jns.1994.81.2.0188. View

13.

Gavrilovic I, Hormigo A, Yahalom J, DeAngelis L, Abrey L . Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006; 24(28):4570-4. DOI: 10.1200/JCO.2006.06.6910. View

14.

DeAngelis L, Yahalom J, Thaler H, Kher U . Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992; 10(4):635-43. DOI: 10.1200/JCO.1992.10.4.635. View

15.

Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M . Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007; 96(6):864-7. PMC: 2360092. DOI: 10.1038/sj.bjc.6603660. View

16.

Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A . Mutational analysis of primary central nervous system lymphoma. Oncotarget. 2014; 5(13):5065-75. PMC: 4148122. DOI: 10.18632/oncotarget.2080. View

17.

Nguyen P, Chakravarti A, Finkelstein D, Hochberg F, Batchelor T, Loeffler J . Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005; 23(7):1507-13. DOI: 10.1200/JCO.2005.01.161. View

18.

Wong E, Tishler R, Barron L, Wu J . Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer. 2004; 101(1):139-45. DOI: 10.1002/cncr.20339. View

19.

Plotkin S, Betensky R, Hochberg F, Grossman S, Lesser G, Nabors L . Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004; 10(17):5643-6. DOI: 10.1158/1078-0432.CCR-04-0159. View

20.

Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J . High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014; 83(3):235-9. PMC: 4117362. DOI: 10.1212/WNL.0000000000000593. View